Translational Development Acquisition Corp. (ticker: TDAC; warrants: TDACW) is a blank-check company with a stated focus on the life sciences and translational medicine sector. The vehicle filed a Form 10-Q with the SEC on August 14, 2025, indicating it remains in active status and has not yet closed a business combination. The name points to a deal mandate centered on healthcare or biotechnology targets that bridge laboratory research and clinical or commercial application, a corner of the SPAC market that has drawn sustained institutional interest. The sponsor behind the company has not been separately identified in available public disclosures. For full filing history, sponsor profiles, and real-time SPAC analytics, sign up for a free account at SpacDesk.